Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TSPO | P30536 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30861230 | 1.00 | HTR2A (0.65) | HTR2AHSD17B10IDO1ADRA1ATAAR1 | |
| Hydrochloric Acid SCHEMBL31327595 | 0.98 | HTR2A (0.63) | HTR2AHSD17B10IDO1ADRA1ATAAR1 | |
| SCHEMBL29519833 | 0.88 | HSD17B10 (0.49) | HTR2AHSD17B10MEN1KMT2ACYP2C9 | |
| Hydrochloric Acid SCHEMBL8862614 | 0.87 | HSD17B10 (0.48) | HTR2AHSD17B10MEN1KMT2ACYP2C9 | |
| SCHEMBL490906 | 0.86 | HSD17B10 (0.66) | HTR2AHSD17B10IDO1ADRA1ATAAR1 | |
| SCHEMBL3659272 | 0.85 | HSD17B10 (0.57) | HTR2AHSD17B10IDO1ADRA1ATAAR1 | |
| SCHEMBL3659269 | 0.85 | HSD17B10 (0.57) | HTR2AHSD17B10IDO1ADRA1ATAAR1 | |
| SCHEMBL13957558 | 0.85 | HSD17B10 (0.45) | HTR2AHSD17B10MEN1KMT2ACYP2C9 | |
| SCHEMBL7303502 | 0.84 | LTA4H (0.64) | HTR2AMEN1KMT2A | |
| SCHEMBL2309888 | 0.84 | CTSD (0.46) | HTR2AHSD17B10MEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20250282712-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI THERAPEUTICS INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12351537-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | ATAI THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240294461-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2024-09-05 | — | — | US | disclosed |
| EP-4351548-A2 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11926574-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | Atai Therapeutics Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117500487-A | Dimethoxy phenyl alkylamine activators of serotonin receptors | 恩泰奥吉尼克斯生物科学公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | PRIESTLEY E SCOTT (DE) | 2004-07-29 | — | — | US | disclosed |
| US-6699855-B2 | PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11926574-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | HTR1A, HTR7, HTR4 | HTR2A 12/4885HSD17B10 1919/4885IDO1 722/4885 |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | HTR2A 12/4885HSD17B10 1919/4885IDO1 722/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | HTR2A 3347/4885HSD17B10 543/4885IDO1 1672/4885 |
| US-12351537-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | HTR1A, HTR7, HTR4 | HTR2A 12/4885HSD17B10 1919/4885IDO1 722/4885 |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | VIP, PRSS1, SERPINB1 | HTR2A 4582/4885HSD17B10 1453/4885IDO1 1004/4885 |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | VIP, PRSS1, CTSC | HTR2A 4637/4885HSD17B10 1157/4885IDO1 851/4885 |
| US-20250282712-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | HTR2A 12/4885HSD17B10 1919/4885IDO1 722/4885 |
| US-20240294461-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | HTR2A 12/4885HSD17B10 1919/4885IDO1 722/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | HTR2A 3915/4885HSD17B10 140/4885IDO1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.